ART Medical News
10 articles
New Clinical Study Shows Unprecedented Results of ART MEDICAL's smART+ Platform, Including Significant Reduction in Length of Stay, Ventilation Days in ICU and Improved Feeding Efficacy
ART MEDICAL, an Israeli medical device company, has unveiled the results of a study demonstrating the effectiveness of its smART+ Platform in improving patient outcomes in intensive care units (ICUs). The study showed that the smART+ Platform can maximize feeding efficiency, reduce ICU length of stay, and reduce length of ventilation. The breakthrough technology is expected to have a significant impact on critical care nutrition. The smART+ Platform is designed to prevent delayed initiation of enteral feeding and assist with tube positioning, energy goal calculation, and detection of reflux events. The study results showed nearly 90% feeding efficiency and improved achievement of daily nutritional targets. The commercialization of the smART+ Platform is a key focus for ART MEDICAL.
Customers
ART MEDICAL Announces Partnership With Teva Israel to Bring Its Lifesaving Technology to Critical Care Units
ART MEDICAL Ltd. has announced a collaboration with Teva Israel to market and distribute ART MEDICALs smART+ Platform in Israels intensive care units. The smART+ Platform is a robotic-assisted technology that aims to improve patient outcomes by addressing complications related to feeding tube malposition, malnutrition, Ventilator-Associated Pneumonia (VAP), and Acute Kidney Injury (AKI). The collaboration with Teva Israel is expected to have a positive impact on the growth of ART MEDICAL. The article discusses the challenges in current intensive care unit practices and how the smART+ Platform provides real-time monitoring and personalized care for critically ill patients. Teva Israel, a leading player in the local health market, is focused on offering innovative and safe treatment options to improve patient health.
Partners
Hillel's Tech Corner: ART MEDICAL's holistic approach to critical care
Art Medical has developed the smART+ Platform, an all-in-one solution for managing the care of mechanically ventilated patients in the ICU. The platform utilizes sensor-based feeding tubes and smart disposables to detect and prevent ventilator-associated pneumonia (VAP) and malnutrition in real-time. The company has collaborated with hospitals in Israel and the US, and a recent case study showed that a popular non-invasive oxygenation method used for COVID-19 patients may increase the risk of aspiration and ICU-acquired pneumonia. Art Medical has raised $46 million in capital from investors and aims to bring critical care into the 21st century by preventing ICU-acquired complications. The companys technology is changing the approach to intensive care nutrition therapy and has been described as a game changer in the world of intensive care nutrition.
CustomersPartners
ART MEDICAL Unveils AI-Based Algorithms to Save ICU Patients' Lives
ART MEDICAL, an Israeli startup, has announced advanced algorithms for their sensor-based smart tubes platform. The algorithms aim to reduce the risks of medical complications by automating the placement of feeding tubes and detecting gastric content aspiration. The technology continuously monitors patients in real-time, alerting medical staff of any abnormalities during tube procedures. This helps to minimize complications and improve clinical outcomes. The algorithms also ensure accurate placement of the feeding tube by monitoring its position in the GI tract. The use of X-ray imaging for identifying tube positioning complications is eliminated. ART MEDICALs smARTrack device, embedded with this technology, has received FDA clearance. The company aims to save lives in hospitals and prevent complications in ICUs unrelated to the original reason for hospitalization.
CustomersPartners
This Israeli startup brings sensor-based smart tubes to the ICU
Art Medical, a medical technology startup, aims to prevent complications in ICU patients through its sensor-based tubes and tech platform. The companys products monitor gastric reflux and saliva in real-time, allowing nurses to intervene when complications arise. Art Medical recently raised $20 million in a funding round led by Advanced Medical Technologies, with the goal of bringing the complete product to the market and reducing ICU lengths of stay. The startup has received CE Mark and FDA approval and is currently undergoing clinical studies in the United States.
Investment
ART Medical Is Selected For The Journal of mHealth's 2017 Global Digital Health 100
Israeli startup creates sensor-based tubes for better patient monitoring
ART Medical has developed sensor-based smart tubes that allow hospitals to avoid complications from intubation in intensive care units. The smart tubes monitor gastric reflux, saliva, and urine output continuously and automatically, alerting nurses and physicians of any abnormalities. The technology has received FDA approval and is in the final stages of clinical trials. Sales of the product are expected to start late next year. ART Medical has raised $27 million to date from investors including Advanced Medical Technologies LLC.
Investment
Art Medical's smart tubes to collect patient data, reduce complications
Israeli biotech company Art Medical is introducing a new platform that collects comprehensive patient data using sensor-based smart tubes to reduce the risk of medical complications in intensive care units. The smart tube technology uses sensors to collect data and adjusts itself to a patient’s individual needs. The platform detects gastric reflux and secretion, which can cause dangerous complications for ICU patients. Art Medical has raised $28 million in investment, including $20 million in a funding round led by Advanced Medical Technologies. The company has been working on connected, sensor-laden tubes to continuously monitor for complications and collect data of patients in the ICU since its founding in 2009.
Investment
ART Medical Unveils Smart Sensor-Based Tubes Platform That Personalizes ICU Care
ART Medical, an Israeli firm, has unveiled its sensor-based smart tubes solutions for comprehensive patient data collection and reduction in risk of medical complications. The company has completed a $20 million funding round led by Advanced Medical Technologies LLC. The platform allows for automated and real-time responses to reduce intubation-related medical complications. The smart tube platform collects patient data, controls the feeding process, and detects and prevents life-threatening problems. ART Medicals technology has received FDA approval and is in the final stages of clinical trials.
Investment
Art Medical seeks to make hospitals safer
Art Medical, an Israeli startup specializing in smart tubes for ICU patients, has raised $20 million in funding. The companys platform of sensor-based smart tubes solutions aims to collect more comprehensive patient data and reduce the risk of medical complications. Art Medical has raised a total of $27 million since its founding in 2008. The companys CEO, Liron Elia, was inspired to start the company after hearing about patients who died from complications after being saved by medical procedures. The smart tubes monitor gastric reflux, saliva, and urine output in real-time to alert healthcare professionals of any abnormalities and prevent complications.
Investment